Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Liabilities and Shareholders Equity (2018 - 2025)

10x Genomics' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 13.36% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $4.0 billion, up 6.55%, while the annual FY2025 figure was $1.0 billion, 13.36% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.0 billion at 10x Genomics, up from $1.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.0 billion in Q4 2025 and bottomed at $903.4 million in Q1 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $984.8 million (2023), against an average of $977.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 67.74% in 2021 before it dropped 8.99% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.0 billion in 2021, then increased by 1.0% to $1.0 billion in 2022, then dropped by 6.2% to $965.1 million in 2023, then fell by 4.82% to $918.6 million in 2024, then grew by 13.36% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for TXG's Liabilities and Shareholders Equity are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $980.0 million (Q2 2025).